IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Rigdon Lentz

Serial No: 09/699,003 Art Unit: 3761

Filed: October 26, 2000 Examiner: Patricia M. Bianco

For: Method and Compositions for Treatment of Cancers

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A CO-PENDING APPLICATION

Sir:

Petitioner, Biopheresis Technologies, Inc. is the owner of the entire interest in the above-identified application and U.S. Patent Application No. 11/153,524 filed on June 14, 2005, as evidenced by the accompanying two (2) Statements Under 37 C.F.R. § 3.73(b). Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173 as shortened by any terminal disclaimer filed prior to the grant of pending U.S. Patent Application No. 11/153,524 filed on June 14, 2005, or any continuations thereof under 37 C.F.R. § 1.53(b). Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it, and any patent granted on pending U.S. Patent Application No. 11/153,524 are commonly owned. This

U.S.S.N. 09:699,003 Filed: Cleoser 26, 2000 TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOCUME PATENTING REJECTION OVER A CO-PENDING APPLICATION

agreement runs with any patent granted on the instant application and is binding upon the

grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of

any patent granted on the instant application that would extend to the expiration date of

the full statutory term as defined in 35 U.S.C. §§ 154-156 and 173 of any patent granted on

pending U.S. Patent Application No. No. 11/153,524 as shortened by any terminal

disclaimer filed prior to the patent grant, in the event that the granted patent: expires for

failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of

competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under

37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is

in any manner terminated prior to the expiration of its full statutory term as shortened by

any terminal disclaimer filed prior to its grant.

The undersigned (whose title is supplied below) is empowered to act on behalf of

Biopheresis Technologies, Inc.

2

LEN 101 CIP CON 077829/00000 U.S.S.N. 09/699,893 FBed: October 26, 2600 TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A CO-PENDING APPLE ATTON

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

BIOPHERESIS TECHNOLOGIES, INC

By:

Name: Patrea L. Pabst; Registration No. 31,284

Title: Attorney of Record

Date: September 15, 2006